SEC Form 4 · accession 0001770252-26-000003
Arcus Biosciences, Inc. · RCUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicole Lambert
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 4:28 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001724521
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 11, 2026 | A | 5,700 | $0.00 | A | 43,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $23.30 | Jun 11, 2026 | A | 16,900 | A | — | Jun 10, 2036 | Stock Option (Rights to Buy) | 16,900 | 16,900 | D |
Explanation of responses
- F1Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
- F2The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.